🇺🇸 FDA
Patent

US 9006222

Natural combination hormone replacement formulations and therapies

granted A61KA61K31/565A61K31/57

Quick answer

US patent 9006222 (Natural combination hormone replacement formulations and therapies) held by Compass Therapeutics LLC expires Mon Apr 09 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Compass Therapeutics LLC
Grant date
Tue Apr 14 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 09 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K31/565, A61K31/57, A61K47/10, A61K47/14